Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis

Archives of Medical Science

Volumn 7, Issue 2, 2011, Pages 189-194

  Puszczewicz, Mariusz ^a   Iwaszkiewicz, Cezary ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

American College of Rheumatology; Anti cyclic citrullinated peptide; Anti mutated citrullinated vimentin; Anti Sa; Antibodies to citrullinated protein peptide; Rheumatoid arthritis

Indexed keywords

CITRULLINATED VIMENTIN ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PROTEIN ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE MARKER; HISTORY; HUMAN; MEDICAL LITERATURE; PHYSICIAN; PREDICTIVE VALUE; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY;

EID: 79956354385     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2011.22067     Document Type: Review

References (59)

1. Whalley D, McKenna SP, de Jong Z, van der Heijde D. Quality of life in rheumatoid arthritis. Br J Rheumatol 1997; 36: 884-8.
2. Eberhardt K, Larsson BM, Nived K, Lindqvist E. Work disability in rheumatoid arthritis - development over 15 years and evaluation of predictive factors over time. J Rheumatol 2007; 34: 481-7. (Pubitemid 46364001)
3. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002; 46: 283-5.
4. Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004; 50: 2072-81. (Pubitemid 38924384)
5. Steiner G, Nell V, Eberl G, et al. Autoantibodies in very early rheumatoid arthritis: diagnostic tools or pathogenic players? Arthritis Res Ther 2003; 5: 118.
6. Landewé R. Predictive markers in rapidly progressing rheumatoid arthritis. J Rheumatol Suppl 2007; 80: 8-15. (Pubitemid 350076863)
7. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
8. Newkirk MM. Rheumatoid factors: what do they tell us? J Rheumatol 2002; 29: 2034-40.
9. Eberhardt KB, Svensson B, Truedsson L, Wollheim FA. The occurrence of rheumatoid factor isotypes in early definite rheumatoid arthritis - no relationship with erosions or disease activity. J Rheumatol 1988; 15: 1070-4.
10. van Zeben D, Hazes JM, Zwinderman AH, Cats A, van der Voort EA, Breedveld FC. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis 1992; 51: 1029-35.
11. Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid Arthritis Classification Criteria. An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 2010; 62: 2569-81.
12. Waaler, E. On the occurrence of a factor in human serum activating the specific agglutination of sheep red corpuscles. Acta Pathol Microbiol Scand 1940; 17: 172-88.
13. Nienhuis RL, Mandema E, Smids C. A new serum factor in patients with rheumatoid arthritis: the antiperinuclear factor. Ann Rheum Dis 1964; 23: 302-5.
14. Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ. Antikeratin antibodies in rheumatoid arthritis. Br Med J 1979; 2: 97-9.
15. Simon M, Girbal E, Sebbag M, et al. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies", autoantibodies specific for rheumatoid arthritis. J Clin Invest 1993; 92: 1387-93.
16. Sebbag M, Simon M, Vincent C, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995; 95: 2672-9.
17. McKinley-Grant LJ, Idler WW, Bernstein IA, et al. Characterization of a cDNA clone encoding human filaggrin and localization of the gene to chromosome region 1q21. Proc Natl Acad Sci USA 1989; 86: 4848-52. (Pubitemid 19182197)
18. Vossenaar ER, Zendman AJW, van Venrooij WJ. Citrullination, a possible functional link between susceptibility genes and rheumatoid arthritis. Arthritis Res Ther 2004; 6: 1-5. (Pubitemid 38256080)
19. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101: 273-81. (Pubitemid 28058927)
20. Girbal-Neuhauser E, Durieux JJ, Arnaud M, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro) filaggrin by deimination of arginine residues. J Immunol 1999; 162: 585-94. (Pubitemid 29018970)
21. Cantaert T, De Rycke L, Bongartz T, et al. Citrullinated proteins in rheumatoid arthritis: crucial but not sufficient! Arthritis Rheum 2006; 54: 3381-9.
22. Masson-Bessière C, Sebbag M, Girbal-Neuhauser E, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001; 166: 4177-84. (Pubitemid 32224951)
23. Vossenaar ER, Després N, Lapointe E, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004; 6: R142-50.
24. Chang X, Yamada R, Suzuki A, Kochi Y, Sawada T, Yamamoto K. Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology (Oxford) 2005; 44: 1374-82. (Pubitemid 41631860)
25. Pratesi F, Tommasi C, Anzilotti C, Chimenti D, Miglio rini P. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54: 733-41.
26. Kinloch A, Tatzer V, Wait R, et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R1421-9.
27. Suzuki A, Yamada R, Ohtake-Yamanaka M, Okazaki Y, Sawada T, Yamamoto K. Anti-citrullinated collagen type I antibody is a target of autoimmunity in rheumatoid arthritis. Biochem Biophys Res Commun 2005; 333: 418-26. (Pubitemid 40848307)
28. Burkhardt H, Sehnert B, Bockermann R, Engström A, Kalden JR, Holmdahl R. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 2005; 35: 1643-52. (Pubitemid 40691444)
29. Hagiwara T, Hidaka Y, Yamada M. Deimination of histone H2 A and H4 at arginine 3 in HL-60 granulocytes. Biochemistry 2005; 44: 5827-34. (Pubitemid 40525119)
30. Tabushi Y, Nakanishi T, Takeuchi T. Detection of citrullinated proteins in synovial fluids derived from patients with rheumatoid arthritis by proteomics-based analysis. Ann Clin Biochem 2008; 45: 413-7. (Pubitemid 352031550)
31. Vossenaar ER, Radstake TR, van der Heijden A, et al. Expression and activity of citrullinating PAD enzymes in monocytes and macrophages. Ann Rheum Dis 2004; 63: 373-81. (Pubitemid 38453302)
32. Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij WJ, Tak PP. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 2004; 50: 3485-94. (Pubitemid 39488673)
33. Makrygiannakis D, af Klint E, Lundberg IE, et al. Citrullination is an inflammation-dependent process. Ann Rheum Dis 2006; 65: 1219-22.
34. Palosuo T, Lukka M, Alenius H, et al. Purification of filaggrin from human epidermis and measurement of antifilaggrin autoantibodies in sera from patients with rheumatoid arthritis by an enzyme-linked immunosorbent assay. Int Arch Allergy Immunol 1998; 115: 294-302. (Pubitemid 28143031)
35. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155-63. (Pubitemid 30368225)
36. van Venrooij WJ, Zendman AJ. Anti-CCP2 antibodies: an overview and perspective of the diagnostic abilities of this serological marker for early rheumatoid arthritis. Clin Rev Allergy Immunol 2008; 34: 36-9.
37. Bang H, Egerer K, Gauliard A, et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007; 56: 2503-11. (Pubitemid 47237269)
38. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann N Y Acad Sci 2008; 1143: 268-85.
39. Mutlu N, Bicakcigil M, Tasan DA, Kaya A, Yavuz S, Ozden AI. Comparative performance analysis of 4 different anticitrullinated protein assays in the diagnosis of rheumatoid arthritis. J Rheumatol 2009; 36: 491-500.
40. Tuchocka-Piotrowska A, Białkowska-Puszczewicz G, Puszczewicz M. The prevalence and diagnostic significance of aCCP antibodies and rheumatoid factor in rheumatoid arthritis patients. Reumatologia 2007; 45: 59-64.
41. Quinn MA, Gough AK, Green MJ, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 2006; 45: 478-80.
42. Shankar S, Grover R, Handa R. Role of anti cyclic citrullinated peptide antibodies in erosive disease in patients with rheumatoid arthritis. Indian J Med Res 2006; 124: 689-96. (Pubitemid 46592110)
43. Alexiou I, Germenis A, Ziogas A, Theodoridou K, Sakkas LI. Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskelet Disord 2007; 8: 37.
44. Meyer O, Labarre C, Dougados M, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003; 62: 120-6. (Pubitemid 36135386)
45. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004; 50: 709-15. (Pubitemid 38326168)
46. van der Helm-van Mil AH, le Cessie S, van Dongen H, Breedveld FC, Toes RE, Huizinga TW. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007; 56: 433-40.
47. Chibnik LB, Mandl LA, Costenbader KH, Schur PH, Karlson EW. Comparison of threshold cut-points and continuous measures of anti-CCP antibodies in predicting future RA. J Rheumatol 2009; 36: 706-11.
48. Ioan-Facsinay A, Willemze A, Robinson DB, et. al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum 2008; 58: 3000-8.
49. Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006; 8: R119.
50. Soos L, Szekanecz Z, Szabo Z, et al. Clinical evaluation of anti-mutated citrullinated vimentinby ELISA in rheumatoid arthritis. J Rheumatol 2007; 34: 1658-63. (Pubitemid 47267606)
51. Mathsson L, Mullazehi M, Wick MC, et al. Antibodies against citrullinated vimentin in rheumatoid arthritis. Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008; 58: 36-45.
52. Poulsom H, Charles PJ. Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis. Clinic Rev Allerg Immunol 2008; 34: 4-10.
53. Damjanovska L, Thabet MM, Levarth EW, et al. Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis 2010; 69: 730-2.
54. Boire G, Cossette P, de Brum-Fernandes AJ, et al. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 2005; 7: R592-603.
55. Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008; 35: 1002-8. (Pubitemid 351813144)
56. Mathsson L, Mullazehi M, Wick MC, et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008; 58: 36-45.
57. Syversen SW, Goll GL, van der Heijde D, et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis 2010; 69: 345-51.
58. Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006; 8: R119.
59. Luime JJ, Colin EM, Hazes JM, Lubberts E. Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis 2010; 69: 337-44.